Idarubicin Accord

Idarubicin, the active ingredient in Idarubicin Accord, is an anthracycline antibiotic presented as a sterile solution for injection for intravenous use. It is employed in the treatment of acute myeloid leukemia, primarily in adult patients, and is marketed within the European Union.

GNH USA supplies Idarubicin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, ensuring quality and regulatory conformity across global markets. The product conforms to EU pharmacopeial standards and is manufactured under GMP conditions.

Idarubicin is an anthracycline used in the management of hematologic malignancies.

Acute Myeloid Leukemia: induces remission and reduces leukemic blast proliferation.

Idarubicin may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting - Fatigue or weakness - Alopecia (hair loss) - Myelosuppression (low blood counts) - Mucositis (mouth inflammation) - Diarrhea

Serious or Rare Side Effects: - Cardiotoxicity (heart failure or reduced ejection fraction) - Severe neutropenia or febrile neutropenia - Life‑threatening hemorrhage - Secondary malignancies (e.g., therapy‑related leukemia) - Anaphylactic or severe hypersensitivity reactions - Acute hepatic dysfunction

Prior to initiating therapy, clinicians should assess patient‑specific risk factors and monitor organ function. - Cardiac monitoring: obtain baseline and periodic echocardiograms or MUGA scans. - Hematologic monitoring: perform regular complete blood counts to detect myelosuppression. - Renal/hepatic function: evaluate liver enzymes and creatinine before each cycle. - Pregnancy and lactation: avoid use; drug is contraindicated in pregnant or breastfeeding individuals. - Drug interactions: review concomitant cardiotoxic or myelosuppressive agents. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Idarubicin can interact with several medicines, influencing safety or efficacy.

Major Interactions (Avoid): - Concurrent anthracyclines: additive cardiotoxicity. - Combination with trastuzumab: heightened risk of cardiac dysfunction. - High‑dose cyclophosphamide: amplified myelosuppression.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma concentrations. - Erythropoietin‑stimulating agents: can mask anemia progression. - Anticoagulants (e.g., warfarin): potential for increased bleeding.